Compare PKOH & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKOH | STTK |
|---|---|---|
| Founded | 1907 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.5M | 275.9M |
| IPO Year | 1994 | 2020 |
| Metric | PKOH | STTK |
|---|---|---|
| Price | $24.40 | $5.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $37.00 | $7.00 |
| AVG Volume (30 Days) | 23.2K | ★ 574.2K |
| Earning Date | 06-11-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $1,599,100,000.00 | $1,000,000.00 |
| Revenue This Year | $6.31 | N/A |
| Revenue Next Year | $4.18 | N/A |
| P/E Ratio | $14.49 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.52 | $0.69 |
| 52 Week High | $29.50 | $6.13 |
| Indicator | PKOH | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 40.92 | 71.75 |
| Support Level | $19.21 | $1.85 |
| Resistance Level | $29.00 | N/A |
| Average True Range (ATR) | 1.37 | 0.40 |
| MACD | -0.40 | 0.17 |
| Stochastic Oscillator | 5.70 | 87.70 |
Park-Ohio Holdings Corp is a company, engaged in industrial supply chain logistics and diversified manufacturing business. It operates in three business segments namely Supply Technologies, Assembly Components and Engineered Products. Geographically, the business of the group is amplifying across the region of the United States, Asia, Europe, Canada, Mexico and others. The company derives key revenue from the Supply Technologies segment which includes proactive solutions approach that manages the efficiencies of every aspect of supplying production parts and materials to customers' manufacturing floor, from strategic planning to program implementation.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.